Expression of a Constitutively Active Erythropoietin Receptor in Primary Hematopoietic Progenitors Abrogates Erythropoietin Dependence and Enhances Erythroid Colony-forming Unit, Erythroid Burst-forming Unit, and Granulocyte/macrophage Progenitor...
Overview
Affiliations
We tested the ability of a constitutively activated erythropoietin receptor [EpoR(R129C)] to alter the growth requirements of primary hematopoietic precursors that terminally differentiate in culture. Two recombinant retroviruses expressing EpoR(R129C), spleen focus-forming virus (SFFVc-EpoR) and myeloproliferative sarcoma virus (MPSVcEpoR), were used to infect fetal liver cells that served as a source of hematopoietic progenitors. Methylcellulose cultures were incubated in the absence of any added growth factors or in combination with selected growth factors. EpoR(R129C) completely abrogated the Epo requirement of erythroid colony-forming units to form erythrocytes after 2-5 days in culture and did not interfere with the differentiation program of these cells. In the absence of added growth factors EpoR(R129C) did not enhance erythroid burst-forming unit development. In contrast to experiments in heterologous cell lines, EpoR(R129C) did not render progenitor cells independent of interleukin 3 or granulocyte/macrophage colony-stimulating factor (GM-CSF). However, when progenitors were cultured with added steel factor, but not with interleukin 3 or GM-CSF, EpoR(R129C) augmented the growth and differentiation of erythroid bursts, mixed erythroid/myeloid, and granulocyte/macrophage (GM) colonies. Furthermore, both viruses were capable of expressing EpoR(R129C) in erythroid, mixed erythroid/myeloid, and GM colonies. Thus an aberrantly expressed and constitutively activated EpoR can stimulate proliferation of some GM progenitors. The ability of EpoR(R129C) to abrogate the Epo requirement of primary hematopoietic cells, but not the requirement for other cytokines, is consistent with the induction of erythroblastosis in vivo.
Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.
Zhang H, Means S, Schultz A, Watanabe-Smith K, Medeiros B, Bottomly D Cancer Res. 2017; 77(16):4258-4267.
PMID: 28652245 PMC: 5763920. DOI: 10.1158/0008-5472.CAN-17-1052.
Shi J, Yuan B, Hu W, Lodish H Exp Hematol. 2016; 44(11):1044-1058.e5.
PMID: 27473563 PMC: 5083198. DOI: 10.1016/j.exphem.2016.07.010.
Erythropoietin receptor contributes to melanoma cell survival in vivo.
Kumar S, Zhang G, Bastian B, Arcasoy M, Karande P, Pushparajan A Oncogene. 2011; 31(13):1649-60.
PMID: 21860424 PMC: 3441831. DOI: 10.1038/onc.2011.366.
The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.
Watowich S J Investig Med. 2011; 59(7):1067-72.
PMID: 21307776 PMC: 3134576. DOI: 10.2310/JIM.0b013e31820fb28c.
Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.
Hardee M, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani Z PLoS One. 2007; 2(6):e549.
PMID: 17579721 PMC: 1891087. DOI: 10.1371/journal.pone.0000549.